Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 69
Filtrar
3.
J Chin Med Assoc ; 86(2): 133-134, 2023 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-36652564
6.
Polymers (Basel) ; 14(23)2022 Nov 22.
Artigo em Inglês | MEDLINE | ID: mdl-36501464

RESUMO

Water that penetrates through cracks in concrete can corrode steel bars. There is a need for reliable and practical seepage sensing technology to prevent failure and determine the necessary maintenance for a concrete structure. Therefore, we propose a modified plasma-assisted electrochemical exfoliated graphite (MPGE) nanosheet smart tag. We conducted a comparative study of standard and modified RFID smart tags with sensor technology for seepage detection in concrete. The performance of both smart tags was tested and verified for seepage sensing in concrete, characterized by sensor code and frequency values. Seepage was simulated by cracking the concrete samples, immersing them for a designated time, and repeating the immersing phase with increasing durations. The test showed that the modified smart tag with 3% MPGE and an additional crosslinking agent provided the best sensitivity compared with the other nanosheet compositions. The presence of 3D segregated structures on the smart tag's sensing area successfully enhanced the sensitivity performance of seepage detection in concrete structures and is expected to benefit structural health monitoring as a novel non-destructive test method.

10.
Taiwan J Obstet Gynecol ; 61(6): 927-934, 2022 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-36427994

RESUMO

Endometriosis, manifested by pain and infertility, is a chronic inflammatory disease, associated with a large disability of daily living, causing a socio-economic diastrophic problem and burden. The main goal of therapy attempts to reduce pain, correct infertility and possibly avoid or delay occurrence of long-term endometriosis-associated sequelae, such as fibrosis, adhesion and malignant transformation. Although the advanced technology (minimally invasive diagnostic tools, magnetic resonance imaging, high-resolution vaginal ultrasound etc.) and the better understanding pathophysiology of endometriosis for development of new therapeutic strategy is continuous for both diagnosis and management of endometriosis, there is still presence of many debated issues, which commonly occur in routine clinical practice. For example, the timing and duration of medications may be one of most frequently discussed issues. In this part I, we would like to overview the general background knowledge (basic concept) about the endometriosis, and emphasize the role of clinical diagnosis and possible empirical medical treatment (therapeutic test) for the management of women with endometriosis.


Assuntos
Endometriose , Infertilidade Feminina , Humanos , Feminino , Endometriose/diagnóstico , Endometriose/terapia , Endometriose/complicações , Infertilidade Feminina/complicações , Ultrassonografia , Doença Crônica , Vagina , Dor
11.
Taiwan J Obstet Gynecol ; 61(6): 951-959, 2022 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-36427997

RESUMO

Endometrial cancer (EC) has become one of rapidly increasing women's cancers, contributing to the most common cancer of the female genital tract in high- and middle-incomed countries, including Taiwan. In general, EC is believed its favorable outcome; however, high-grade endometrial cancers have a tendency to recur and also have a high risk to be presented as an advanced stage or accompanied with metastatic lesions, which result in a biggest therapeutic challenge. The standard therapy includes complete staging surgery (sentinel node sampling)/optimal debulking surgery, and subsequent adjuvant therapy, by either radiotherapy locally or systemic therapy as chemotherapy or targeted therapy, or in combination or in subsequential strategy is made based on the risk stratification using clinicopathological prognostic factors. All efforts are made to minimize the risk of recurrence and possible therapeutic failure. In this part I, we would like to overview the general background knowledge (basic concept) about the cancer of uterine corpus, and discuss the recent transformation to patients-tailored therapy based on modern molecular technology as the optimal strategy to balance the therapeutic efficacy and treatment-related toxicity. Optimally, it is possible to reach the best benefits.


Assuntos
Neoplasias do Endométrio , Feminino , Humanos , Neoplasias do Endométrio/patologia , Terapia Combinada , Taiwan
12.
J Chin Med Assoc ; 2022 Oct 21.
Artigo em Inglês | MEDLINE | ID: mdl-36279128

RESUMO

Type 2 diabetes mellitus (DM) is characterized by inability of faulty pancreatic ß-cells to secret a normal amount of insulin to maintain normal body consumption, and/or peripheral tissue has a decreased susceptibility to insulin, resulting in hyperglycemia and insulin resistance. Similar to other chronic systemic inflammatory diseases, DM is a result from dysregulated interactions between ethnic, genetic, epigenetic, immunoregulatory, hormonal and environmental factors. Therefore, it is rational to suppose the concept as "To do one and to get more", while using anti-diabetic agents (ADA), a main pharmacologic agent for the treatment of DM, can provide an extra-glycemia effect on co-morbidities or concomittent co-morbidities to DM. In this review, based on the much strong correlation between DM and metabolic dysfunction-associated fatty liver diseases (MAFLD) shown by similar pathophysiological mechanisms and a high prevalence of DM in MAFLD and its vice versa (a high prevalence of MAFLD in DM), it is possible to use the strategy to target both diseases simultaneously. We focus on a new classification of ADA, such as glucagon-like peptide 1 receptor (GLP1R) agonist and sodium-glucose cotransporter-2 (SGLT-2) inhibitors to show the potential benefits of extra-glycemic effect on MAFLD. We conclude that the management of DM patients, especially for those who need ADA as adjuvant therapy should include healthy lifestyle modification to overcome the metabolic syndrome, contributing to the urgent need of an effective weight reduction strategy. GLP1R agonist is one of effective body weight-lowering medications, which may be a better choice for DM complicated with MAFLD or its-associated severe form as MASH, although the role of SGLT-2 inhibitors are also impressive. The prescription of these two classes of ADA may satisfy the concept "To do one and to get more", based on successful sugar-lowering effect for controlling DM and extra-glycemia benefits of hepatoprotective activity in DM patients.

13.
Micromachines (Basel) ; 13(9)2022 Sep 19.
Artigo em Inglês | MEDLINE | ID: mdl-36144177

RESUMO

This study optimized the field plate (FP) design (i.e., the number and positions of FP layers) of p-GaN power high-electron-mobility transistors (HEMTs) on the basic of simulations conducted using the technology computer-aided design software of Silvaco. Devices with zero, two, and three FP layers were designed. The FP layers of the HEMTs dispersed the electric field between the gate and drain regions. The device with two FP layers exhibited a high off-state breakdown voltage of 1549 V because of the long distance between its first FP layer and the channel. The devices were subjected to high-temperature reverse bias and high-temperature gate bias measurements to examine their characteristics, which satisfied the reliability specifications of JEDEC.

14.
J Chin Med Assoc ; 85(10): 965-971, 2022 10 01.
Artigo em Inglês | MEDLINE | ID: mdl-36066352

RESUMO

Type 2 diabetes mellitus (T2DM), is a chronic metabolic disease, characterized by the presence of hyperglycemia and insulin resistance. The key treatment strategies for T2DM include modification of lifestyle, medications, and continuous glucose monitoring. DM patients often have DM-associated morbidities and comorbidities; however, disorders of musculoskeletal system are often neglected, compared to other major systems in DM patients. Based on sharing similar pathophysiology of DM and osteoporosis, it is supposed that the use of antidiabetic agents (ADAs) may not only provide the lowering glucose level effect and the maintenance of the sugar homeostasis to directly delay the tissue damage secondary to hyperglycemia but also offer the benefits, such as the prevention of developing osteoporosis and fractures. Based on the current review, evidence shows the positive correlation between DM and osteoporosis or fracture, but the effectiveness of using ADA in the prevention of osteoporosis and subsequent reduction of fracture seems to be inconclusive. Although the benefits of ADA on bone health are uncertain, the potential value of "To do one and to get more" therapeutic strategy should be always persuaded. At least, one of the key treatment strategies as an establishment of healthy lifestyle may work, because it improves the status of insulin resistance and subsequently helps DM control, prevents the DM-related micro- and macrovascular injury, and possibly strengthens the general performance of musculoskeletal system. With stronger musculoskeletal system support, the risk of "fall" may be decreased, because it is associated with fracture. Although the ADA available in the market does not satisfy the policy of "To do one and to get more" yet, we are looking forward to seeing the continuously advanced technology of drug development on diabetic control, and hope to see their extra-sugar-lowering effects.


Assuntos
Diabetes Mellitus Tipo 2 , Fraturas Ósseas , Hiperglicemia , Resistência à Insulina , Osteoporose , Glicemia , Automonitorização da Glicemia , Diabetes Mellitus Tipo 2/tratamento farmacológico , Fraturas Ósseas/complicações , Humanos , Hiperglicemia/complicações , Hipoglicemiantes/uso terapêutico , Osteoporose/complicações , Osteoporose/prevenção & controle
16.
J Chin Med Assoc ; 85(11): 1061-1067, 2022 11 01.
Artigo em Inglês | MEDLINE | ID: mdl-36083636

RESUMO

BACKGROUND: Oxytocin is commonly used to reduce blood loss during suction curettage for missed abortion. However, the potential of oxytocin to mitigate blood loss in early pregnancy remains controversial. Based on the hypothesis that the "timing" of oxytocin administration may be a critical factor, we investigated whether the timing of intravenous (IV) administration is associated with reduced perioperative blood loss during first-trimester suction curettage for missed abortion. METHODS: The medical charts of 146 patients with ultrasound-confirmed first-trimester missed abortion who underwent suction curettage with IV oxytocin administration were retrospectively reviewed. RESULTS: Among the patients, 67 received 10 IU of IV oxytocin before suction curettage (early-oxytocin administration group), while 79 patients received 10 IU of IV oxytocin after suction curettage (late-oxytocin administration group). The demographic features between the two groups did not significantly differ. However, there was a lower proportion of nulliparous patients in the early-oxytocin administration group than in the late-oxytocin administration group (38.8% vs 60.8%, p = 0.006). The perioperative blood loss amount was significantly lower in the early-oxytocin administration group than in the late-oxytocin administration group (60 [range: 50-100] vs 100 [range: 30-250] mL, p = 0.001). Moreover, the multivariate logistic regression analysis showed that the early-oxytocin administration group had a lower risk for a perioperative blood loss amount of ≥100 mL than the late-oxytocin administration group (0.23 [range: 0.10-0.55], p = 0.001); a gestational age of 9-12 weeks ( p = 0.009) was found to be associated with an increased risk for a perioperative blood loss amount of ≥100 mL. CONCLUSION: Compared with late-oxytocin administration, early-oxytocin administration could reduce perioperative blood loss during first-trimester suction curettage for missed abortion. However, the results require further investigation.


Assuntos
Aborto Induzido , Aborto Retido , Gravidez , Feminino , Humanos , Lactente , Curetagem a Vácuo , Primeiro Trimestre da Gravidez , Aborto Retido/prevenção & controle , Ocitocina , Estudos Retrospectivos , Perda Sanguínea Cirúrgica
18.
Taiwan J Obstet Gynecol ; 61(5): 911-912, 2022 09.
Artigo em Inglês | MEDLINE | ID: mdl-36088069
19.
Kidney Int ; 102(4): 780-797, 2022 10.
Artigo em Inglês | MEDLINE | ID: mdl-35934136

RESUMO

Plasma levels of angiopoietin-2 are increased in patients with chronic kidney disease (CKD). Moreover, mouse models of progressive kidney disease also demonstrate increased angiopoietin-2 in both plasmas and kidneys. The role of dysregulated angiopoietins in the progression of kidney disease has not been thoroughly investigated. Here, we found in a cohort of 319 patients with CKD that plasma angiopoietin-2 and angiopoietin-2/angiopoietin-1 ratios were positively associated with the development of kidney failure. In mice with progressive kidney disease induced by either ureteral obstruction or ischemia-reperfusion injury, overexpression of human angiopoietin-1 in the kidney tubules not only reduced macrophage infiltration in the initial stage post-injury but also attenuated endothelial cell apoptosis, microvascular rarefaction, and fibrosis in the advanced disease stage. Notably, angiopoietin-1 attenuated chemokine C-C motif ligand 2 (CCL2) expression in the endothelial cells of the fibrosing kidneys, and these protective effects led to attenuation of functional impairment. Mechanistically, angiopoietin-1 reduced CCL2-activated macrophage migration and protected endothelial cells against cell apoptosis induced by angiopoietin-2 and Wnt ligands. Based on this, we applied L1-10, an angiopoietin-2 inhibitor, to the mouse models of progressive kidney disease and found inhibitory effects on macrophage infiltration, microvascular rarefaction, and fibrosis. Thus, we defined the detrimental impact of increased angiopoietin-2 on kidney survival of patients with CKD which appears highlighted by angiopoietin-2 induced endothelial CCL2-activated macrophage infiltration and endothelial cell apoptosis in their kidneys undergoing fibrosis.


Assuntos
Rarefação Microvascular , Insuficiência Renal Crônica , Angiopoietina-1 , Angiopoietina-2/metabolismo , Animais , Apoptose , Quimiocina CCL2/metabolismo , Quimiocinas/metabolismo , Células Endoteliais/patologia , Fibrose , Humanos , Rim/patologia , Ligantes , Camundongos , Camundongos Endogâmicos C57BL , Rarefação Microvascular/metabolismo , Rarefação Microvascular/patologia , Insuficiência Renal Crônica/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...